Advertisement

Medikamentöse Therapie neuromuskulärer Erkrankungen

  • D. Rating
Conference paper

Zusammenfassung

Aus der großen Gruppe neuromuskulärer Krankheiten können nur einige der Erkrankungen, d.h. die Duchenne’sche Muskeldystrophie, die Myasthenia gravis, die Dermatomyositis und die Mitochondriozytopathien herausgegriffen und ihre möglichen medikamentösen Therapien dargestellt werden. Auf andere Entitäten dieses Formenkreises, wie die übrigen Spielarten der Muskeldystrophien, auf die spinalen Muskelatrophien, die maligne Hyperthermie, die verschiedenen myotonen Erkrankungen kann hier nicht eingegangen werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Albers JW, Faulkner JA, Dorovini-Zis K et al. (1984) Abnormal neuromuscular transmission in an infantile myasthenic syndrome. Ann Neurol 16: 28–34PubMedCrossRefGoogle Scholar
  2. Argov Z, Bank WJ, Maris Jet al. (1986) Treatment of mitochondrial myopathy due to complex IIl deficiency with vitamins K3 and C: a 31P NMR follow-up study. Ann Neurol 19: 598–602PubMedCrossRefGoogle Scholar
  3. Bäckman E, Nylander E, Johansson I et al. (1988) Selenium and vitamin E treatment of Duchenne muscular dystrophy: no effect on muscle function. Acta Neurol Scand 78: 429–435Google Scholar
  4. Barnard PJ, Barnard EP (1980) Chemotherapy in the genetically dystrophic chicken with a neurotrophic drug with serotonin antagonists. In: Angelini et al. (eds) Muscular dystrophy research: advances and trends. Excerpta Medica Amsterdam, pp 242–248Google Scholar
  5. Bertorini TE, Bhattacharya SK, Palmieri GM et al. (1982) Muscle calcium and magnesium content in Duchenne muscular dystrophy. Neurology (NY) 32: 1088–1092Google Scholar
  6. Bertorini TE, Palmieri GMA, Griffin JW et al. (1988) Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy. Neurology 38: 609–613PubMedGoogle Scholar
  7. Bodensteiner JB, Engel AG (1978) Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567.000 muscle fibers in 114 biopsies. Neurology (Minneap) 28: 439–446Google Scholar
  8. Bohan A. Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292: 344–347, 403–407CrossRefGoogle Scholar
  9. Bohan A, Peter JB, Bowman RRL (1977) A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 56: 255–286PubMedCrossRefGoogle Scholar
  10. Bondoux-Jahan M, Hügelin A (1982) Acceleration par l’isaxonine du bourgeonnement collateral au niveau du muscle partiellement denerve. Nouv Presse Med 11: 1243–1245PubMedGoogle Scholar
  11. Brambati B, Cornelio F, Dworzak F, Dones I (1980) Calcium-positive muscle fibers in fetuses at risk for Duchenne muscular dystrophy Lancet II: 969–970Google Scholar
  12. Bresolin N. Bet L, Binda A et al. (1988) Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme QIO. Neurology 38: 892–899PubMedGoogle Scholar
  13. Brooke MH, Griggs RC, Mendell JR et al. (1981) Clinical trial in Duchenne dystrophy: I. The design of the protocol. Muscle Nerve 4: 186–187Google Scholar
  14. Brooke MH, Fenichel GM, Griggs RC et al. (1983) Clinical investigation in Duchenne dystrophy: II. Determination of the “power” of therapeutic trials based on the natural history. Muscle Nerve 6: 91–103PubMedCrossRefGoogle Scholar
  15. Brooke MH, Fenichel GM, Griggs RC et al. (1987) Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol 44: 812–817PubMedGoogle Scholar
  16. Bunch TW (1981) Prednisone and azathioprine for polymyositis: long-term follow up. Arthritis Rheum 24: 45–48PubMedCrossRefGoogle Scholar
  17. Bunch TW, Worthington JW, Combs JJ et al. (1980) Azathioprine with prednisone for polymyositis. A con trolled, clinical trial. Ann Intern Med 92: 365–369PubMedGoogle Scholar
  18. Chan-Lui WY, Hawkins BR (1985) Infantile myasthenia. Neuropediatrics 16: 24–28PubMedCrossRefGoogle Scholar
  19. DeSilva S, Drachman DB, Mellits D, Kund R (1987) Prednisone treatment in Duchenne muscular dystrophy. Long term benefit. Arch Neurol 44: 818–822PubMedGoogle Scholar
  20. Drachman DB, Toyka KV, Myer E (1974) Prednisone in Duchenne muscular dystrophy. Lancet II: 1409–1412Google Scholar
  21. Dubowitz V, Heckmatt JZ (1980) Management of muscular dystrophy: pharmacological and physical aspects. Br Med Bull 36: 139–144PubMedGoogle Scholar
  22. Engel AG, Lambert EH, Gomez MR (1977) A new myasthenic syndrome with endplate acetylcholine-esterase deficiency, small nerve terminals and reduced acetylcholine release. Ann Neurol 1: 315–330PubMedCrossRefGoogle Scholar
  23. Engel AG, Lambert EH, Mulder DM et al. (1982) A newly recognised congenital myasthenic syndrome attributed as a prolonged open-time of the acetylcholine-induced ion channel. Ann Neurol 11: 553–569PubMedCrossRefGoogle Scholar
  24. Fenichel GM, Brooke MH, Griggs RC et al. (1988) Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E. Muscle Nerve 11: 1164–1168CrossRefGoogle Scholar
  25. Fitzgerald G, McArdle B (1941) Vitamins E and B6 in the treatment of muscular dystrophy and motor neurone disease. Brain 64: 19–42Google Scholar
  26. Gamstorp I, Gustaysson KH, Hellström O, Nordgren B (1986) A trial of selenium and vitamin E in boys with muscular dystrophy. J Child Neurol 1: 211–214Google Scholar
  27. Gieron MA, Korthals JK (1985) Familial infantile myasthenia gravis. Arch Neurol 42: 143–144PubMedGoogle Scholar
  28. Girardin E, Dayer JM, Paunier L (1988) Cyclosporin for juvenile dermatomyositis. J Pediatr 112: 165–166PubMedGoogle Scholar
  29. Goda S, Hamada T, Ishimoto S et al. (1987) Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 234: 62–63PubMedCrossRefGoogle Scholar
  30. Hart Z, Sahashi K. Lambert EH et al. (1979) A congenital familial myasthenic syndrome caused by a presynaptic defect of transmitter resynthesis or mobilisation. Neurology 29: 556–557Google Scholar
  31. Heckmatt JZ, Hyde SA, Gabain A, Dubowitz V (1988) Therapeutic trial of isaxonine in Duchenne muscular dystrophy. Muscle Nerve 11: 836–847PubMedCrossRefGoogle Scholar
  32. Heckmatt J, Saunders C, Peters AM et al. (1989) Cyclosporin in juvenile dermatomyositis. Lancet I: 1063–1066Google Scholar
  33. Hugelin A, Legrain Y, Bondous-Jahan M (1979) Nerve growth promoting action of isaxonine in rat. Experientia 35: 626PubMedCrossRefGoogle Scholar
  34. Jacobs JC (1977) Methotrexate and azathioprine treatment of childhood dermatomyositis. Pediatrics 59: 212–218PubMedGoogle Scholar
  35. Keesey J, Lindstrom J, Cokely H, Hermann C (1977) Anti-acetylcholine receptor antibody in neonatal myasthenia gravis. N Engl J Med 296: 55PubMedGoogle Scholar
  36. Langsjoen PH, Folkers K, Lyson K et al. (1988) Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenschr 66: 583–590PubMedCrossRefGoogle Scholar
  37. Law PK, Goodwin TG, Wang MG (1988) Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle Nerve 11: 525–533PubMedCrossRefGoogle Scholar
  38. Law PK, Bertorini TE, Goodwin JA et al. (1990a) Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy. Lancet II: 114Google Scholar
  39. Law PK, Fang R, Goodwin JA et al. (1990b) First clinical trial of myoblast transfer therapy. J Neurol Sci 98 (Suppl): 32Google Scholar
  40. Lecky BRF, Morgan-Hughes JA, Murray NMF et al. (1986) Congenital myasthenia: further evidence of disease heretogeneity. Muscle Nerve 9: 233–242PubMedCrossRefGoogle Scholar
  41. Lefvert AK, Osterman PO (1983) Newborn infants to myasthenic mothers: a clinical study and an investigation of acetylcholine-receptor antibodies in 17 children. Neurology 33: 133–138PubMedGoogle Scholar
  42. Malleson PN, Ansell BM, Miller J, Pachman LM, Sullivan DB (1990) Controversies in juvenile dermatomyositis. J Rheumatol 17 (Suppl 22): 1–6Google Scholar
  43. Mendell JR, Province MA, Moxley RT (1987) Clinical investigation of Duchenne muscular dystrophy. Arch Neurol 44: 808–811PubMedGoogle Scholar
  44. Mendell JR, Moxley RT, Griggs RC et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne’s muscular dystrophy. N Engl J Med 320: 1592–4597PubMedCrossRefGoogle Scholar
  45. Morel E, Eymard B, Vernet-der-Garabedian B et al. (1988) Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology 38: 138–142PubMedGoogle Scholar
  46. Moxley RT, Brooke MH, Fenichel GM et al. (1987) Clinical investigation in Duchenne dystrophy. VI. Double-blind controlled trial of nifedipine. Muscle Nerve 10: 22–33Google Scholar
  47. Nakao K, Nishitani H, Susuki M, Ohta M, Hayashi K (1977) Anti-acetylcholine receptor IgG in neonatal myasthenia gravis. N Engl J Med 297: 169PubMedCrossRefGoogle Scholar
  48. Namba T, Brown SB, Grob D (1970) Neonatal myasthenia gravis: report of two cases and review of literature. Pediatrics 45: 488–505PubMedGoogle Scholar
  49. Niakan E, Pitner SE, Whitaker JN (1980) Immunosuppressive agents in corticosteroidrefractory childhood dermatomyositis. Neurology 30: 286–291PubMedGoogle Scholar
  50. Nishikawa Y, Takahashi M, Yorifuji S et al. (1989) Long-term coenzyme 010 therapy for a mitochondrial encephalomyopathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 39: 399–403PubMedGoogle Scholar
  51. Ogasahara S, Nishikawa Y, Yorifuji S et al. (1986) Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurology 36: 45–53PubMedGoogle Scholar
  52. Ohta K, Muzuno Y (1988) Pathogenesis of progressive muscular dystrophy: studies on free radical metabolism in an animal model. Acta Neurol Scand 77: 108–114PubMedCrossRefGoogle Scholar
  53. Pachman LM (1986) Juvenile dermatomyositis. Pediatr Clin North Am 33: 1097–1117PubMedGoogle Scholar
  54. Pernice W, Beckmann R, Ketelsen UP et al. (1988) A double-blind placebo controlled trial of diltiazem in Duchenne dystrophy. Klin Wochenschr 66: 565–570PubMedCrossRefGoogle Scholar
  55. Przyrembel H (1987) Therapy of mitochondrial disorders. J Inher Metabol Dis 10: 129–146CrossRefGoogle Scholar
  56. Roach ES, Buono G, McLean W, Weaver RG (1986) Early-onset myasthenia gravis. J Pediatr 108: 193–197PubMedCrossRefGoogle Scholar
  57. Robinson BH, Taylor J, Francois B, Beaudet AL, Peterson DF (1983) Lactic acidosis, neurological deterioration and compromised cellular pyruvate oxidation due to a defect in the reoxidation of cytoplasmically generated NADH. Eur J Pediatr 140: 98–101PubMedCrossRefGoogle Scholar
  58. Shay JW, Feit H (1980) Avian muscular dystrophy: microtubules, righting ability, CPK levels and muscle histology following isaxonine treatment. Eur J Cell Biol 22: 557Google Scholar
  59. Siegel IM, Miller JE, Ray RD (1974) Failure of corticosterone in the treatment of Duchenne muscular dystrophy: Report of a clinically matched three-year double blind study. IMJ 145: 32–36Google Scholar
  60. Vincent A, Cull-Candy SG, Newsom-Davis J et al. (1981) Congenital myasthenia: endplate receptors and electrophysiology in five cases. Muscle Nerve 4: 306–318PubMedCrossRefGoogle Scholar
  61. Walton JN, Nattrass FJ (1954) On the classification, natural history and treatment of the myopathies. Brain 77: 169–231PubMedCrossRefGoogle Scholar
  62. Yarom R, Meyer S, More R, Liebergall M, Eldor A (1983) Platelet abnormalities in muscular dystrophy. Thromb Haemost 49: 168–172PubMedGoogle Scholar
  63. Yoshida M, Ando K, Stoyoshi E (1983) Abnormalities of erythrocytes in Duchenne muscular dystrophy. Ann Neurol 13: 649–653PubMedCrossRefGoogle Scholar
  64. Zabel P, Leimenstoll G, Gross WL (1984) Cyclosporin for acute dermatomyositis. Lancet 1: 343PubMedCrossRefGoogle Scholar
  65. Zierz S, Jahns G, Jerusalem F (1989) Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus. J Neurol 236: 97–101PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • D. Rating

There are no affiliations available

Personalised recommendations